Results 21 to 30 of about 32,832 (202)

Targeting FGFR for cancer therapy

Journal of Hematology & Oncology
The FGFR signaling pathway is integral to cellular activities, including proliferation, differentiation, and survival. Dysregulation of this pathway is implicated in numerous human cancers, positioning FGFR as a prominent therapeutic target.
Pei Zhang, Lin Yue, QingQing Leng, Chen Chang, Cailing Gan, Tinghong Ye, Dan Cao   +6 more
doaj   +3 more sources

FGFR alterations and potential role of FGFR inhibitors in pediatric brain tumors. [PDF]

Neurooncol Adv
Abstract A wide spectrum of genomic events leading to dysregulated fibroblast growth factor receptor (FGFR) signaling have been reported across low-grade and high-grade glial/glioneuronal tumors. These events include structural alterations, such as gene fusions and duplications, as well as recurrent mutations in FGFR1–3.
Sait SF, Bale T, Karajannis MA.
europepmc   +2 more sources

FGFR/RACK1 interacts with MDM2, promotes P53 degradation, and inhibits cell senescence in lung squamous cell carcinoma

Cancer Biology & Medicine, 2021
Objective: FGFR is considered an important driver gene of lung squamous cell carcinoma (LSCC). Thus, identification of the biological events downstream of FGFR is important for the treatment of this malignancy.
Tao Chen, Fei Wang, Shupei Wei, Yingjie Nie, Xiaotao Zheng, Yu Deng, Xubin Zhu, Yuezhen Deng, Nanshan Zhong, Chengzhi Zhou   +9 more
doaj   +1 more source

Resistance to Selective FGFR Inhibitors in FGFR- Driven Urothelial Cancer

Cancer Discovery, 2023
Abstract Several fibroblast growth factor receptor (FGFR) inhibitors are approved or in clinical development for the treatment of FGFR-driven urothelial cancer, and molecular mechanisms of resistance leading to patient relapses have not been fully explored.
Francesco Facchinetti, Antoine Hollebecque, Floriane Braye, Damien Vasseur, Yoann Pradat, Rastislav Bahleda, Cédric Pobel, Ludovic Bigot, Olivier Déas, Juan David Florez Arango, Giorgia Guaitoli, Hayato Mizuta, David Combarel, Lambros Tselikas, Stefan Michiels, Sergey I. Nikolaev, Jean-Yves Scoazec, Santiago Ponce-Aix, Benjamin Besse, Ken A. Olaussen, Yohann Loriot, Luc Friboulet   +21 more
openaire   +3 more sources

Recent Advances in Tumor Therapy Targeting FGFR

Zhongliu Fangzhi Yanjiu, 2022
Abnormal FGFR signaling has been found in a variety of cancers. The abnormal FGFR signaling is involved in several processes of tumorigenesis which include cell survival, proliferation, inflammation, migration, angiogenesis, epithelial-mesenchymal ...
ZHANG Jing, WANG Chen, GU Baohong, ZHANG Yaqing, CHEN Hao   +4 more
doaj   +1 more source

Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases

Cancer Biology & Medicine, 2021
Objective: Dysfunction in fibroblast growth factor receptor (FGFR) signaling has been reported in diverse cancer types, including non-small cell lung cancer (NSCLC).
Zhen Zhou, Zichuan Liu, Qiuxiang Ou, Xue Wu, Xiaonan Wang, Yang Shao, Hongyan Liu, Yu Yang   +7 more
doaj   +1 more source

Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study. [PDF]

, 2022
BACKGROUND Patients with advanced squamous-cell lung cancer (SQCLC) frequently (46%) exhibit tumor overexpression of fibroblast growth factor receptor (FGFR) messenger ribonucleic acid (mRNA). Rogaratinib is a novel oral pan-FGFR inhibitor with a good
Calgua, Byron, Waibel, Christine, Jermann, Philip M, Haefliger, Simon, Alborelli, Ilaria, Joerger, Markus, Mach, Nicolas, Addeo, Alfredo, Savic-Prince, Spasenija, Holer, Lisa, Fernandez, Eugenio, Rothschild, Sacha I, Mauti, Laetitia, Früh, Martin, Mark, Michael, Schneider, Martina   +15 more
core   +1 more source

Favorable Outcomes in FGFR Fusion-Positive Cholangiocarcinomas and Evolution on Treatment Noted on Circulating Tumor DNA Liquid Biopsies

Case Reports in Oncology, 2020
Cholangiocarcinoma is a very heterogenous cancer and “target-rich” disease. While the current classifications are based on the anatomic location of these tumors (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer ...
Pashtoon Murtaza Kasi
doaj   +1 more source

Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment

Molecular Cancer, 2023
Background Fibroblast growth factors (FGFs) and their receptors (FGFRs) play a crucial role in cell fate and angiogenesis, with dysregulation of the signaling axis driving tumorigenesis. Therefore, many studies have targeted FGF/FGFR signaling for cancer
Ruiwen Ruan, Li Li, Xuan Li, Chunye Huang, Zhanmin Zhang, Hongguang Zhong, Shaocheng Zeng, Qianqian Shi, Yang Xia, Qinru Zeng, Qin Wen, Jingyi Chen, Xiaofeng Dai, Jianping Xiong, Xiaojun Xiang, Wan Lei, Jun Deng   +16 more
doaj   +1 more source

Expression of FGFR-2 and FGFR-3 in the normal human fetal orbit [PDF]

British Journal of Ophthalmology, 2005
To demonstrate the expression patterns of two fibroblast growth factor receptors (FGFR-2 and FGFR-3) in the normal human fetal orbit.6 microm orbital slide sections were prepared from 12 week old human fetal material obtained within established ethical guidelines.
S H, Khan, J A, Britto, R D, Evans, K K, Nischal   +3 more
openaire   +2 more sources